SkinCure Oncology Launches GentleBeam™ to Enhance Skin Cancer Treatment Precision
SkinCure Oncology Introduces GentleBeam™ for Enhanced Precision in Skin Cancer Treatment
In an exciting development in dermatology, SkinCure Oncology has launched GentleBeam™, a cutting-edge technology recently cleared by the FDA, aimed specifically at improving treatment accuracy for nonmelanoma skin cancer. This innovative tool enhances the existing Image-Guided Superficial Radiation Therapy (IGSRT) framework, providing practitioners with advanced visualization capabilities essential for effective treatment planning and execution.
The GentleCure Experience™
At the heart of SkinCure Oncology's mission is the GentleCure Experience™, a comprehensive model designed to deliver personalized, noninvasive radiation therapy for patients with skin cancer. With the introduction of GentleBeam™, the company aims to bolster the efficacy of this model by integrating enhanced imaging technology that allows for better visualization of skin layers and blood vessels.
Kerwin Brandt, CEO of SkinCure Oncology, emphasized the importance of this new technology, stating, "GentleBeam uses a unique Photosonic™ technology that generates acoustic pressure waves, allowing physicians to visualize treatment areas with remarkable precision. This capability is vital in not just planning but confirming the successful eradication of tumors."
Improved Treatment Outcomes
The addition of GentleBeam™ is a significant step towards improving patient outcomes in dermatology. Studies backing IGSRT report an impressive cure rate surpassing 99% for well-selected cases of nonmelanoma skin cancer, affirming the reliability of SkinCure's approach. Brandt noted, "This launch reflects our commitment to continuously upgrading our service offerings to ensure we deliver state-of-the-art solutions tailored for our dermatological partners."
Dr. Daniel Ladd, Chief Medical Officer at SkinCure, underscored the advantages of GentleBeam™ in the context of cost-effective patient care. He remarked that radiation therapy administered under an IGSRT model yields better cure rates compared to traditional hospital-based therapies, such as electron beam therapy, while also being more affordable for both healthcare providers and patients.
Personalization of Treatment
The technology is expected to revolutionize how dermatologists approach skin cancer treatment, allowing for a more personalized care experience. The enhanced imaging capabilities of GentleBeam™ mean that practitioners can fine-tune their treatment strategies to align with each patient's specific needs. This level of customization ultimately aims at elevating the GentleCure Experience™ for every patient seeking care.
SkinCure Oncology has positioned itself as a leader in the realm of skin cancer treatment by combining expertise in radiation therapy with innovative technology. With over 500 affiliated physicians nationwide having treated upwards of 140,000 patients through this initiative, the company continues to set new standards in non-surgical cancer treatment methodologies.
For more information on SkinCure Oncology and its services, visit SkinCureOncology.com. For insights about the GentleCure Experience™, check out GentleCure.com.
This dynamic enhancement in dermatological practices promises to pave the way for innovative solutions in cancer treatment, reinforcing the importance of technology-driven approaches in modern healthcare.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.